NPPA and cardiovascular disorder: NEP enzyme is inhibited by Sacubitril (NEP inhibitor) and elevates several beneficial NEP substrates (such as ANP, BNP, GLP-1) in cardiovascular diseases, suggesting pleiotropic effects of treatment [13, 33–35].